Stay up to date on recent advances in oncology nursing and patient care.
Proactive Management of NALIRIFOX-Related Diarrhea Is Crucial in Metastatic PDAC
Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
Maintenance OSE2101 With Chemo Reaches Primary OS End Point in PDAC
Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.
Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.
FDA Approves Tislelizumab Combo for Advanced ESCC
The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.
Perioperative FLOT Improves Survival in Resectable Esophageal Carcinoma
Perioperative chemotherapy improved survival compared with preoperative chemoradiotherapy in managing esophageal cancer.
Risk Factors Determine Symptom Burden Profiles by Age Group
Study Findings Support D-VRd for Transplant-Ineligible or -Deferred MM
Real-World Data Shows Apalutamide Increases 24-Month OS in mCSPC
Mobile App Appears Feasible for Cancer Survivor Cognitive Assessment Function
